Eargo

Eargo is a commercial-stage medical device company disrupting the traditional hearing aid market through a direct-to-consumer (DTC) model. The company's core innovation lies in its 'virtually invisible,' in-canal hearing aids, which are sold online and supported by remote customer care, aiming to reduce cost and stigma. While it successfully gained FDA clearances and built a brand, Eargo has faced significant financial and legal challenges, including a high-profile DOJ investigation into insurance billing practices. Its future hinges on stabilizing operations under Chapter 11 restructuring and proving the long-term viability of its capital-light, DTC approach in a competitive landscape.

Direct-to-consumer platform combining proprietary, virtually invisible in-canal hearing aid hardware with a mobile app for self-assessment, sound personalization, and remote telehealth support.

Eargo operates in a highly competitive arena. It faces direct competition from other DTC hearing aid companies (e.g., Audicus, Lively), but the greater threat may come from established consumer electronics brands like Bose, Sony, and Jabra, which now offer FDA-regulated OTC hearing devices with strong brand recognition and retail distribution. Traditional hearing aid giants (Sonova, Demant) also defend their market with clinical partnerships and are launching their own DTC offerings.